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Abstract
Estrogen signaling is required for the proliferation of normal breast epithelial cells. However, prophylactic inhibition of
estrogen signaling fails to prevent 56% of human breast cancer cases. The underlying mechanism is not well under-
stood. Aberrant activation of growth factor signaling is known toprovide alternative proliferation pathways in breast cells
that are fully transformed, but it is not known whether activation of growth factor signaling can substitute for estrogen
signaling in causing aberrant proliferation in the normal breast epithelium. Here, we report that in a retrovirus-based
somatic mousemodel (replication-competent ALV-LTR splice acceptor/tumor virus A) that closely mimics the evolution
of sporadic human breast cancers, mammary epithelial cells harboring PyMT or activated ErbB2 evolve into tumors in-
dependent of estrogen or other ovarian functions in contrast to previous observations of estrogen-dependent cancer
formation in germ line mouse models of ErbB2 activation. Importantly, ErbB2 activation in normal mammary cells
causes estrogen-independent proliferation in both estrogen receptor (ER)–negative cells aswell as in normally quiescent
ER-positive cells. Therefore, aberrant activation of growth factor signaling contributes to estrogen-independent prolifer-
ation of both preneoplastic and cancerous mammary cells, and prophylactic therapy against both growth factor signal-
ing and estrogen signaling may need to be considered in women with increased risk of breast cancer.
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Introduction
Estrogen receptor α (referred to as ER hereafter) is produced in approx-
imately 15% of mammary epithelial cells in the human breast [1]. Estro-
gen and estrogen signaling through ER are required for the development
of the mammary gland and proliferation of mammary epithelial cells in
the normal breast. Paradoxically, however, proliferation is rarely found in
ER+ cells, but rather in ER− cells. It is generally considered that the bind-
ing of estrogen, released primarily from the ovaries, causes ER to trans-
activate genes whose products act through a paracrine mechanism to
stimulate proliferation of neighboring ER− cells [2,3].ER is also expressed
in at least a fraction of tumor cells in approximately 70%of human breast
tumors [4]. In these tumors, ER+ cells are no longer quiescent but usually
still depend on ovarian estrogen for proliferation.
Prophylactic suppression of estrogen signaling in high-risk women
reduces the occurrence of breast cancer. However, treatment with the
antiestrogens tamoxifen or raloxifene only decreases the incidence of
breast tumors in these women by 44% [5]. Thus, in many patients,
mutated breast cells can progress to cancer unhindered in the absence
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of estrogen signaling. The molecular mechanism underlying such a
clinical observation is not well understood. ErbB2 (Her2, Neu) en-
codes a member of the epidermal growth factor receptor family of
receptor tyrosine kinases and is amplified in 20% to 25% of human
breast cancers [6]. Studies using mouse xenografts of cultured human
breast cancer cell lines suggest that activation of ErbB2 or members
of other growth factor signaling pathways can result in estrogen-
independent growth of established breast tumor cells that normally
require estrogen for proliferation [7–11], providing a mechanistic ex-
planation for the failed prevention of some breast cancers using anti-
estrogens. However, it is not known whether activation of ErbB2 or
other components of growth factor signaling in ER+ or ER− cells in
the normal breast epithelium is sufficient to cause these normal cells
to undergo aberrant proliferation and tumor evolution independent
of estrogen signaling. If so, this could provide a complementary ex-
planation and would suggest that estrogen-independent proliferation
may occur at any stage of breast cancer evolution when growth factor
signaling is activated.
In transgenic mice expressing ErbB2 from the mouse mammary
tumor virus (MMTV) LTR, a ubiquitously active mammary-selective
promoter, administration of tamoxifen starting at the age of 12 weeks
delayed mammary tumor development [12]. In accord, ovariectomy at
the age of 2 months also decreased the tumor incidence in this trans-
genic line [13]. These observations suggest that ErbB2-induced mam-
mary tumorigenesis may still depend on estrogen signaling. However,
it is not known whether suppression of clinical tumor formation in
these models is due to an estrogen requirement for the initial aberrant
proliferation of precancerous mammary cells or for expansion from
nascent cancerous cells to a palpable tumor.
Further complicating the interpretation of these results, these and
other genetically engineered models suffer oncogenic changes before
pubertal mammary development [14], and the development of a nor-
mal ductal tree is impaired [15,16]. Besides, the widespread oncogenic
expression in most mammary epithelial cells in these germ line models
fails to closely mimic the initiation of sporadic human breast cancers,
which arise in a fewmutated cells among a field of normal breast cells in
a normally developed breast, although most of these models eventually
develop stochastic tumors. In addition, commonly used promoters for
mammary transgenic expression, such as the MMTV LTR or the pro-
moter driving the gene encoding whey acidic protein, are hormone-
responsive [17–19]. Consequently, attenuation of estrogen signaling
may decrease the expression levels of the transgenic oncogene, compli-
cating the interpretation of these transgenic tumor studies.
We therefore asked whether tumorigenesis initiated by ErbB2 or
the gene encoding polyoma virus middle T antigen (PyMT ), which
activates overlapping signaling pathways with ErbB2, still depends on
estrogen signaling in a somatic mouse model that more closely mimics
the evolution of sporadic human breast cancers. This somatic model
was recently adapted by us from the tumor virus A (TVA)–mediated
gene transfer technique for generating mouse models of breast cancer
with both spatial and temporal controls [20–23]. Transgenic mice
were made to express the gene encoding the retroviral receptor TVA
in the mammary epithelium from the MMTV LTR. An avian retro-
viral vector (replication-competent ALV-LTR splice acceptor, RCAS)
was used to infect and deliver oncogenes selectively into mammary
epithelial cells producing TVA. Consequently, cancers evolve from
one or a few oncogene-activated cells in an otherwise normal mammary
epithelium in this model [22]. Because carcinogenesis in this model
more closely recapitulates the evolution of sporadic human breast can-
cers from breast cells with somatically activated growth factor signal-
ing, we used it in this report to test whether ErbB2 or PyMT-induced
mammary tumorigenesis requires estrogen signaling for any phase of
tumor formation.
Materials and Methods
Mice
TheMMTV-tva transgenic line has been previously described [21].
All animals used in this study were of the FVB/N genetic background.
Mice were kept in specific pathogen-free housing with abundant food
and water according to National Institutes of Health guidelines.
Virus Preparation
The RCAS vector carrying PyMT (RCAS-PyMT) has been de-
scribed [24]. RCAS-ErbB2 contains the rat ErbB2 DNA insert with
a Val 664 point mutation to Glu and truncations in both the extra-
cellular and intracellular domains [25]. This ErbB2 insert contains a
double-HA tag as well as the ovalbumin tag SIINFEKL, which was
not expected to cause any immune response in the FVB/N strain of
mice used in this study. RCAS–β-actin was generated by inserting the
HA-tagged β-actin gene [26] (a gift from Tom Kristie, National Insti-
tutes of Health) into RCAS. To produce RCAS viruses, DF-1 chicken
fibroblasts [27,28] were transfected with RCAS vectors using Superfect
(Qiagen,Hilden,Germany), andmaintained inDulbeccomodified Eagle
medium supplemented with 10% fetal bovine serum and penicillin-
streptomycin in humidified 37°C incubators supplemented with 5%
CO2. Viruses in the culture supernatant were concentrated 100-fold
by centrifugation at 125,000g for 90minutes, resuspended inDulbecco
modified Eagle medium containing 10% fetal bovine serum, and frozen
in aliquots for titer determination and infection of cells and animals.
Virus titers were determined by limiting dilution in DF-1 cells [29].
Tumor Latency Studies
RCAS-PyMT (104 IU) or RCAS-ErbB2 (1.5 × 106 IU) was delivered
into the nos. 2, 3, and 4 mammary glands through intraductal injec-
tion [29] into pubertal (6 weeks) or adult (12-15 weeks) MMTV-tva
mice. A tracking dye (0.1% bromophenol blue) was used to determine
injection success. One week after infection, mice were randomized,
and either ovariectomy or sham surgery was performed. These infected
mice were palpated daily (PyMT ) or three times weekly (ErbB2) for
tumors. For tamoxifen studies, RCAS-PyMTor RCAS-ErbB2 was de-
livered into the nos. 2, 3, and 4 mammary glands through intraductal
injection into pubertal (6 weeks) or adult (10-12 weeks) MMTV-tva
mice, respectively. One week after infection, mice were randomized,
and either tamoxifen or vehicle was introduced as previously described
[30]. Mice infected with RCAS-PyMT were monitored for tumors
daily, and mice infected with RCAS-ErbB2were monitored for tumors
three times per week.
Tissue Harvest and Analysis
Mammary glands and tumors were removed and either fixed in
10% buffered formalin overnight at 4°C or snap frozen in liquid ni-
trogen. Fixed tissues were embedded in paraffin, and 3-μm sections
were used for hematoxylin and eosin staining and/or immunostain-
ing. Western blot analysis was performed as previously described
[30]. Scion Image (Scion Corporation, Frederick, MD) was used for
Western blot quantitation. Primary antibodies used in these studies
include rabbit immunoglobulin G (IgG) against ER (1:500, SC-452;
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Santa CruzBiotechnology, Santa Cruz, CA), Ki67 (1:500,NCL-Ki67-P;
Novacastra, Newcastle upon Tyne, UK), progesterone receptor (PR,
1:500, A0098; Dako, Glostrup, Denmark), phospho-p44/42 mitogen-
activated protein kinase (MAPK; 1:1000, 9101; Cell Signaling, Danvers,
MA), p44/42 MAPK (1:1000, 9102; Cell Signaling), phospho-AKT
(1:1000, 9271; Cell Signaling), AKT (1:1000, 9272; Cell Signaling),
HA (1:1000, PRB-101P; Covance, Princeton, NJ), and glyceraldehyde
2-phosphate dehydrogenase (GAPDH; 1:2000, sc25778; Santa Cruz
Biotechnology); and mouse monoclonal antibodies against Ki67
(1:200, 556003; BD, Franklin Lanes, NJ), and HA (1:500, MMS-
101P; Covance). For immunohistochemical staining, sections were
deparaffinized and rehydrated in a graded xylene/ethanol series and
then stained using the Vector ABC immunostaining kits (Vector Labora-
tories, Burlingame, CA) according to the manufacturer’s instructions. For
immunofluorescent staining, deparaffinized slides were incubated with
primary antibodies for 1 hour at room temperature. After three washes
with Tris-buffered saline supplemented with 0.05% Tween 20 (TBST),
slides were incubated with fluorophore-conjugated secondary anti-
bodies for 30 minutes at room temperature, washed with Tris-buffered
saline supplemented with 0.05% Tween 20, and counterstained with
4′,6-diamidino-2-phenylindole (DAPI) to identify nuclei.
Statistical Analysis
A generalized Wilcoxon test was used in all tumor latency studies.
Student’s t tests were used for comparison of ER status of early lesions
and tumors, tumor proliferation studies, and forWestern blot analysis.
Wilcoxon signed rank tests were used for comparisons of proliferation
rates between early lesions and normal ducts. Wilcoxon rank sum tests
were used for comparison of proliferation rates between intact and
ovariectomized mice.
Results
RCAS-Mediated Gene Expression Is Detected in Both ER+
and ER− Mammary Epithelial Cells in MMTV-tva Mice;
RCAS-PyMT Leads to ER+ Mammary Tumors in the
Majority of Infected MMTV-tva Mice
Our previous studies showed that in MMTV-tva mice, only 0.3%
of mammary cells were infected after intraductal injection of 107 IU
of RCAS virus [21]. Because ER− cells are the majority of mammary
epithelial cells and are the subset of cells undergoing proliferation [1], a
state that is preferred for infection by retroviruses such as RCAS [31], we
first tested whether besides ER− cells, ER+ cells were also infected after
intraductal injection of RCAS. RCAS–β-actin (containing the HA epi-
tope) was injected into 6- and 12-week-old MMTV-tva mice (n = 4
and 9, respectively) at 106 IU per gland, and the infected glands were col-
lected 4 days later for immunofluorescent staining for ER. ER+mammary
cells constituted 34% ± 11% of mammary epithelial cells at the age of
6 weeks and 37% ± 10% at the age of 12 weeks (Figure 1B). Among
the infected cells identified by the HA tag, 49% ± 4% were also positive
for ER at the age of 6 weeks (Figure 1, A and B), and 43 ± 16%were posi-
tive for ER at the age of 12 weeks (Figure 1B). These observations suggest
that this virus infects both ER+ and ER− cells, although we cannot exclude
the possibility that the ER status of some of the originally infected cells had
changed by the time the mammary glands were collected for these assays.
We have previously induced mammary tumors using RCAS virus ex-
pressing the gene encoding PyMT (RCAS-PyMT ) [21], a potent viral
oncoprotein that activates MAPK and phosphoinositide 3-kinase path-
ways, both of which are activated by receptors associated with growth fac-
tor signaling [32]. Intraductal injection of RCAS-PyMT (107 IU) led to
the formation of well-differentiated mammary tumors with a median la-
tency of 12 days [21]. Because well-differentiated tumors in humans usu-
ally express ER [33–35], we asked whether preneoplastic lesions and
tumors induced by RCAS-PyMT also produced ER. Six-week-old
MMTV-tva mice (n = 5) were intraductally injected with RCAS-PyMT
(107 IU per gland). Four days later, the infected glands were collected for
immunohistochemical staining for ER. About 74% of the early lesions in
these infected glands harbored at least 5% ER+ cells (Figure 1C), demon-
strating that delivery of PyMTusing this virus induces predominately ER+
preneoplastic lesions. This is consistent with the finding that ER is pro-
duced in most premalignant breast lesions in human patients [4], regard-
less of the eventual tumor ER status, as well as in several transgenic and
knockout mouse models of breast cancer [30,36–38].
We next examined the ER status of tumors induced by RCAS-
PyMT infection (107 IU). ERwas detected in the nuclei of 5% ormore
of tumor cells in 70% (23/33) of tumors fromMMTV-tvamice infected
at the age of 6 weeks (Figure 1,C andD) and in 61% (25/41) of tumors
from mice infected at the age of 12 weeks (Figure 1D). Therefore, these
tumors were defined as ER+. In addition to ER, these tumors also pro-
duced PR (Figure 1C and data not shown), a classic transcriptional tar-
get of ER, suggesting that estrogen signaling is intact in these ER+ tumor
cells. Collectively, these studies establish that somatic introduction of
PyMTusing this viral approach predominately induces ER+ mammary
early lesions and tumors.
Estrogen-Independent Evolution of Tumors Induced
by RCAS-PyMT
Having found that RCAS-PyMT induces predominately ER+ early
lesions and tumors in the mammary gland, we next asked whether
estrogen deprivation prevents or delays tumorigenesis in this somatic
model. A cohort of twenty-six 6-week-old MMTV-tva mice was in-
jected with RCAS-PyMT at a low dose (104 IU/gland) into one set of
nos. 2, 3, and 4 glands. This dose was estimated to infect much fewer
cells than the 107 IU used in our previous studies, thus allowing any
potential differences in tumor latency caused by ovariectomy to be
more pronounced. Seven days later, animals were randomized for
ovariectomy (n = 13) or sham (n = 13) surgery. These mice were then
palpated daily for tumor appearance. The Kaplan-Meier tumor-free
survival plot is shown in Figure 2A. Sham-treated mice developed
stochastic tumors with a median latency of 39 days. Tumors in ovari-
ectomized mice arose with a median latency of 35 days, not signifi-
cantly different from the control mice (P = .47).
In chemoprevention and treatment of human breast cancer, sup-
pression of estrogen signaling is usually achieved by the administration
of pharmacological inhibitors such as tamoxifen. Therefore, we also
tested whether tamoxifen could prevent tumorigenesis induced by
PyMT. A cohort of 47 pubertal mice was infected with RCAS-PyMT
(107 IU/gland). One week after infection, the mice were treated with
either tamoxifen or vehicle, and tumorigenesis was monitored daily. As
with ovariectomy, tamoxifenwas unable to prevent tumorigenesis in these
mice (P = .2; Figure W1A). Collectively, these data suggest that the re-
moval of ovarian hormones by ovariectomy or attenuation of estrogen
signaling with tamoxifen cannot prevent or delay tumor evolution if
PyMT is introduced somatically intomammary epithelial cells at puberty.
In the human breast, although initiating oncogenic mutations may
start to accumulate at the onset of puberty, tumor initiation is expected
to occur predominately during adulthood. By intraductal injection of
RCAS-PyMT into the mammary glands of five adult (12 weeks old)
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MMTV-tvamice, we generated early lesions 4 days after infection. Of
these early lesions, 54% were designated ER+ by immunohistochem-
istry (IHC; data not shown). We next tested whether tumor
development in these adult mice depended on intact estrogen signaling.
We infected thirty-two 12-week-old MMTV-tva mice with RCAS-
PyMT (104 IU per gland; one set of nos. 2, 3, and 4 glands per mouse).
One week later, mice were randomized, and either ovariectomy (n = 15)
or sham surgery (n = 17) was performed. Mice were palpated daily
for tumor appearance. Tumors appeared with a median latency of 28
and 31 days in the infected mice treated with sham surgery or ovariec-
tomy, respectively (P = .55; Figure 2B). Thus, ovariectomy also does not
affect tumor latency in adult mice after the gain of PyMT. Tumors aris-
ing in these ovariectomized mice were histologically similar to those
arising in the intact mice (data not shown). The rate of ER+ tumor for-
mation was also similar between these two groups of mice: 69% (9/13)
were ER+ in the intact mice, whereas 61% (11/18) were ER+ in the
ovariectomized mice (data not shown). PR was also detected in all of
the ER+ subset of mammary tumors in intact mice (data not shown).
As expected, most (15/18) of tumors from the ovariectomized mice
were PR− (data not shown). These data suggest that estrogen is dispens-
able for the initiation and development of tumors somatically induced
by PyMT.
Estrogen-Independent Evolution of Tumors Induced
by RCAS-ErbB2
Having demonstrated estrogen-independent tumorigenesis induced
by somatic introduction of PyMT, we next tested whether estrogen sig-
naling was required for tumor evolution initiated by an oncogene re-
sponsible for many human breast cancers, ErbB2. We have previously
reported that RCAS (107 IU) encoding an activated version of ErbB2
induced mammary tumors in adult MMTV-tva mice with a median
latency of 6 months [21]. Here, a double HA-tagged (for ease of de-
tection by IHC and immunofluorescence), activated version of ErbB2
was cloned into RCAS, and the resulting RCAS-ErbB2 virus was used
for in vivo experiments. We first determined whether ER was still pro-
duced in mammary cells infected by RCAS-ErbB2 because there is
Figure 1. RCAS-mediated gene expression is detected in both ER+ and ER− mammary epithelial cells in MMTV-tva mice; RCAS-PyMT
leads to ER+mammary tumors inmost infectedMMTV-tvamice. (A and B) Pubertal (n=4; 6weeks) and adult (n=9; 12weeks)MMTV-tva
mice were infected with RCAS–β-actin (HA-tagged) and killed 4 days later. Coimmunofluorescent staining for HA (green) and ER (red) was
performed on the infected glands. A merged image that includes the DAPI nuclear counterstain is shown for an infected mammary gland
from a 6-week-old mouse (A). A costained cell is indicated by a yellow arrow, and a non-costained cell is indicated by a white arrow. Bar
graph (B) shows the percentage of ER+ cells in the general epithelium or among the infected cells (identified by staining for HA). (C) Six-week-
old MMTV-tvamice (n = 5) were infected with RCAS-PyMT and killed 4 days later. Immunohistochemical staining for the indicated proteins
was performedon the resulting early lesions aswell as 33 tumors induced by infecting 6-week-oldmicewith RCAS-PyMT (107 IU). (D) Dot plot
showing the percentage of ER+ cells in these tumors as well as in tumors (n= 41) generated by intraductal injection of RCAS-PyMT (107 IU)
into 12-week-old MMTV-tvamice. Horizontal bar indicates the median value.
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often an inverse correlationwithErbB2 expression andER in breast cancer
[39], and ErbB2 has been reported to suppress ER expression in cultured
breast cancer cell lines [40]. Adult MMTV-tva mice (12-14 weeks)
were infected with RCAS-ErbB2 and RCAS–β-actin in contralateral
glands and were killed either 4 days (n = 9) or 14 days (n = 4) later,
when mild and more advanced hyperplasias were apparent, respectively.
Coimmunofluorescent staining for ER and HA (Figure 3A) was used to
determine the frequency of ER+ cells among infected cells. At day 4 after
infection, ER was detected in 43% ± 16% of RCAS–β-actin–infected
cells, but only in 24% ± 15% of RCAS-ErbB2–infected cells, an al-
most 50% reduction (P = .005; Figure 3B). At day 14, the percentage
of ER+ cells did not change significantly in either group of infected
cells—48% ± 26% RCAS–β-actin–infected cells and 21% ± 20%
RCAS-ErbB2–infected cells—again an approximate 50% reduction
(P = .006). These observations suggest that ErbB2 activation in normal
mammary cells may suppress ER in at least a subset of these cells.
To determine the effect of ovariectomy on tumor induction by
RCAS-ErbB2, 68 adult MMTV-tvamice (12-15 weeks) were infected
with this virus (1.5 × 106 IU per gland, one set of nos. 2, 3, and
4 glands per mouse). One week later, they were randomized, and either
ovariectomy (n = 35) or sham surgery (n = 33) was performed. Tumor
development in these infected mice was monitored by palpation. In
sham-treated mice, tumors developed with a median latency of 90 days,
and the ovariectomizedmice developed tumors with amedian latency of
70 days (Figure 3D). Generalized Wilcoxon analysis found no differ-
ence in tumor latency between sham-treated and ovariectomized mice
(P = .44). In addition, we asked whether tamoxifen could prevent
tumorigenesis induced by somatic activation of ErbB2. One week after
infection with RCAS-ErbB2, 28 adult MMTV-tvamice were random-
ized and were treated with either tamoxifen (n = 15) or vehicle (n = 13).
As with ovariectomy, tamoxifen also failed to prevent or delay tumor-
igenesis in this model (P = .3; Figure W1B). Therefore, somatic acti-
vation of ErbB2 in mammary epithelial cells does not require estrogen
signaling for tumorigenesis.
As predicted from the ubiquitous nature of the RCAS LTR, ErbB2
was made in similar amounts in RCAS-ErbB2–induced early lesions
in both intact and ovariectomized mice (Figure W2A). Likewise,
ErbB2 levels were similar between tumors arising in intact mice versus
those arising in ovariectomized mice, based on Western blot analysis
(P = .4), although the level varied among individual tumors within
both groups of tumors, perhaps representing the different degrees of
stroma infiltration (Figure W2, B and C ). In accord, phosphorylation
of Erk, a critical event downstream of ErbB2, was unaffected in these
tumors by ovariectomy (FigureW3,A and B). Phosphorylation of Akt,
another event downstream of ErbB2, is slightly reduced by ovariectomy
(P = .05; FigureW3, C andD). Estrogen signaling has been reported to
activate Akt through transcription-independent, membrane signaling
[41–43]. Perhaps the loss of membrane signaling from ER in the ovari-
ectomized mice led to this modest reduction of activated Akt in the
tumors. Nevertheless, estrogen signaling does not seem to contribute
much to the growth of these ErbB2-initiated tumor cells: ER was pro-
duced in 5% or more of tumor cells in 21% (4/19) of these tumors
arising in intact mice, and half of these ER+ tumors were also found
to be PR+ (Figure 3C ), but the proliferation rate of the ER+ tumors
was comparable to that of ER− tumors in these mice, based on Ki67
staining (P = .5; Figure W4).
RCAS-ErbB2 Induces Estrogen-Independent Proliferation of
ER− Mammary Epithelial Cells as Well as of a Subset of
Normally Quiescent ER+ Mammary Epithelial Cells
The lack of estrogen dependence in this RCAS-ErbB2 model sug-
gests that aberrant activation of ErbB2 in normal mammary epithelial
cells confers a proliferative advantage that is not compromised even
after the loss of estrogen signaling. To test whether this is indeed the case,
we infected 18MMTV-tvamice (12-15 weeks) with RCAS-ErbB2 and
performed ovariectomy on half of the infectedmice and sham surgery on
the other half 1 week after infection. Two weeks after surgery, the mice
were killed, and immunofluorescent staining for Ki67was performed on
the paraffin sections of these infected glands (Figure 4A). As expected,
cells in the early lesions exhibited a higher proliferation rate (26%± 9%)
than those in the normal ducts in contralateral noninfected glands
(17% ± 12%; P = .04; Figure 4B). This higher proliferation rate in early
lesions did not decrease significantly after ovariectomy (26% ± 9% in in-
tact mice vs 20% ± 8% in ovariectomized mice, P = .14), whereas as ex-
pected, the percentage of proliferating cells in noninfectedmammaryducts
was significantly reduced after ovariectomy (17% ± 12% in intact mice vs
6%±3% in ovariectomizedmice,P= .03; Figure 4C ). These observations
suggest that ErbB2 activation in normal mammary cells causes estrogen-
independent mammary cell proliferation and aberrant expansion.
To investigate whether ErbB2-induced estrogen-independent pro-
liferation occurred in ER− cells, ER+ cells, or both, we performed coim-
munofluorescence for ER and Ki67 in early lesions as well as in the
normal ducts in the contralateral glands as a baseline control (Fig-
ure 4A). As expected, ovariectomy reduced the proliferation of normal
Figure 2. Estrogen-independent evolution of tumors induced by
RCAS-PyMT. (A and B) MMTV-tva mice at the age of 6 (A) or 12 (B)
weeks were infected with RCAS-PyMT (104 IU/gland, one set of
nos. 2-4 glands per mouse). One week later, the infected mice were
randomized and treated with ovariectomy or sham surgery. Tumor
appearance was monitored by daily palpation.
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ER− cells: 22% ± 15% were found to proliferate in the intact glands,
but only 8% ± 4% were proliferative in the ovariectomized glands
(P = .04; Figure 4C ). Also as expected, normal ER+ cells in noninfected
glands in both the intact and ovariectomized mice had very low pro-
liferation rates: 0.8% ± 1.3% and 1.5% ± 4% were found in the intact
glands and ovariectomized glands, respectively (P = .73; Figure 4C ). In
early lesions in intact mice, ER− cells proliferated at a rate of 33% ±
12%, much higher than the proliferation rate of the ER− cells (22% ±
15%) in contralateral uninfected glands (P = .04; Figure 4B), and this
high rate was not significantly affected by ovariectomy (from 33% ±
12% to 26% ± 11%, P = .30; Figure 4C ). These data suggest that
aberrant ErbB2 signaling causes ER− mammary epithelial cells to un-
dergo estrogen-independent proliferation.
In early lesions in intact mice, ER+ cells had a proliferation rate of
6% ± 3%, much higher than the approximately 0.8% observed in ER+
cells in the contralateral uninfected glands (P = .008; Figure 4B), dem-
onstrating that ErbB2 activation in largely quiescent ER+ mammary
epithelial cells can induce at least some of them to undergo prolifera-
tion. Ovariectomy reduced this aberrant proliferation in ER+ cells to
2.9% ± 2.0% (P = .02; Figure 4C ); however, this rate was still higher
than the low basal proliferation rate (0.8% ± 1.3%) detected in normal
mammary epithelium in intact mice (P = .02), suggesting that at
least some of the ErbB2-activated ER+ cells can undergo estrogen-
independent proliferation.
Discussion
By delivering PyMTor activated ErbB2 into a small number of somatic
mammary cells, we generated both ER+ and ER−mammary tumors in
mice. ER was produced in most tumors induced by RCAS-PyMT in
pubertal and adult mice and in a smaller proportion of tumors arising
in adult mice infected by RCAS-ErbB2. These two models add to the
relatively short list of mouse models of ER+ human breast cancers,
which comprise approximately 70% of all human breast cancer cases
[4]. These ER+ models may be useful for elucidating the molecular
mechanisms of anti–hormone resistance found in a subset of human
ER+ tumors. Moreover, 50% of ErbB2+ human breast cancers produce
ER, but no ER has been reported in transgenic models of ErbB2+ hu-
man breast cancers. Therefore, our RCAS-ErbB2model may be a valu-
able in vivomodel for understanding howErbB2 causes ER+ tumors and
why these tumors are inherently resistant to antiestrogenic therapies.
Figure 3. Estrogen-independent evolution of tumors induced by RCAS-ErbB2. (A and B) MMTV-tva mice (12-14 weeks) were injected
intraductally with RCAS-ErbB2 (HA-tagged) and with RCAS–β-actin (HA-tagged) in the contralateral glands. Mice were killed 4 (n = 9) or
14 days (n = 4) later. Coimmunofluorescence for HA and ER was performed on infected glands (A). Scale bar, 20 μm. Bar graph (B) shows
percentage of HA+ cells that were also stained positive for ER. **P< .01. (C) IHC for ER and PRwas performed on tumors arising from intact
mice in (D). Representative images for ER−/PR− tumors and ER+/PR+ tumors are shown. The fractions of cases stained positive or negative
for either ER or PR are indicated. Scale bar, 20 μm. (D) 68MMTV-tvamice (12-15 weeks) were infected with RCAS-ErbB2 (1.5× 106 IU/gland,
one set of nos. 2-4 glands per mouse). One week after infection, mice were randomized, and either ovariectomy or sham surgery was per-
formed. Tumor appearance was monitored three times weekly to obtain tumor-free survival curves.
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Ovariectomy or tamoxifen treatment was unable to prevent or
delay tumorigenesis induced by either PyMT or ErbB2 (Figures 2,
3, and W1), demonstrating that somatic activation of growth factor
signaling through these two oncoproteins causes estrogen-independent
breast tumor formation. This finding suggests that aberrant growth
factor signaling causes normal mammary cells to undergo estrogen-
independent proliferation. Indeed, at 3 weeks after the activation of
ErbB2, estrogen-independent proliferation was detected in ER− cells
and in at least some of the ER+ cells (Figure 4). These findings suggest
that prophylactic antiestrogenic treatment fails to slow tumor evolution
shortly after activation of growth factor signaling. Furthermore, estrogen
signaling does not seem to provide a proliferation benefit to the resulting
tumors (Figure W4). In accord, it has been reported that stable expres-
sion of ErbB2 in the ER+MCF7 human breast cancer cells causes them
to become estrogen-independent or tamoxifen-resistant [8,44–46].
Whereas most epithelial cells in the normal breast epithelium be-
came independent of estrogen for proliferation after they had activated
ErbB2, a small subset of the ER+ cells remained dependent on estrogen
for proliferation (Figure 4). However, these cells most likely did not
contribute significantly to tumor formation in these ovariectomized
or intact mice in our experiments because of the observed estrogen-
independent nature of tumorigenesis and the similar proliferation rate
between ER+ and ER− tumors arising in these mice. We do not yet
know whether tumor evolution might be slowed by ovariectomy if
ErbB2 could be selectively targeted to the ER+ subset of mammary
epithelial cells. In addition, we do not know whether estrogen signal-
ing may have contributed to ErbB2-induced tumor initiation in the
first few days after ErbB2 activation, as ovariectomy or tamoxifen treat-
ment was performed 1 week after infection—this length of time was
chosen to ensure the completion of infection and thus the same rate of
infection in the ovariectomized versus intact mice.
Our results demonstrating estrogen-independent tumor initiation
from ErbB2-activated mammary cells differ from the outcomes of
prevention experiments performed using MMTV-ErbB2 transgenic
mice, in which tamoxifen or ovariectomy delayed tumor appearance
if given before subclinical tumor formation [12,13]. There are several
potential explanations for this difference. In MMTV-tva mice, ErbB2
was targeted by the RCAS vector to a small subset of mammary cells in
developmentally normal mammary glands, whereas in MMTV-ErbB2
transgenic mice, oncogene expression occurs in most mammary epi-
thelial cells and presumably starts before the onset of puberty [14].
It is unlikely that tumor initiation would occur before the onset of
puberty in humans without hereditary mutations. Furthermore,
MMTV-driven activation of ErbB2 results in impaired development
of the mammary gland including incomplete filling of the mammary
fat pad as late as the age of 13 weeks [15,16], suggesting that the nor-
mal cellular milieu in which human breast tumors usually originate is
already compromised in this germ line transgenic model.
Alternatively, RCAS virus may have induced mammary tumors
from a subset of mammary cells different from the cell origin of tumors
in MMTV-ErbB2 transgenic mice. Although the same MMTV pro-
moter is used both to drive ErbB2 in the transgenic model and to dic-
tate the spectrum of cells that express tva and are susceptible to
infection by RCAS in the our TVA model, the cell distribution pat-
terns of MMTV-regulated transgenes in the mammary epithelium
can vary between lines because of the different transgene integration
sites. Mammary tumors induced by RCAS-PyMT contain heteroge-
neous cell types, implying a progenitor origin [21], but tumors arising
Figure 4. RCAS-ErbB2 induces estrogen-independent proliferation of ER− mammary epithelial cells as well as a subset of normally
quiescent ER+ mammary epithelial cells. (A-C) MMTV-tva mice (12-16 weeks; n = 18) were infected with RCAS-ErbB2. One week later,
mice were randomized, and ovariectomy or sham surgery was performed. After another 2 weeks, both infected and noninfected glands
were collected. Coimmunofluorescence was performed for ER and Ki67 (A). A costained cell is indicated by a yellow arrow. Scale bar,
20 μm. Bar graphs show the proliferation rates in total cells in addition to the ER− and ER+ subsets of cells in uninfected glands and
early lesions in intact mice (B), and the proliferation rates in the indicated subsets of cells in intact and ovariectomized mice (C). *P = .01
to .05; **P < .01.
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in MMTV-PyMT and MMTV-ErbB2models are more homogeneous
and are thought to originate frommore differentiated cells [21,47–51].
Because the cell origin of breast cancer has been reported to affect tu-
mor histopathology, cellular heterogeneity, gene expression profiles,
and the metastatic potential of the resulting tumors [52], the potential
difference in the cellular origin between this somatic model and the
transgenic models may also contribute to the difference in dependence
on estrogen signaling. Indeed, if ErbB2 were selectively targeted to the
subset of RCAS-ErbB2–infected ER+ cells whose proliferative capacity
was reduced by ovariectomy, tumor development might be attenuated
on estrogen withdrawal. It will also be interesting to test if estrogen
dependence is observed if ErbB2 or PyMT is introduced through
RCAS infection into differentiation stage–defined mammary cells
using cell subtype–specific (such as stem, progenitor, or alveolar) trans-
genic promoters to control the expression of tva. Finally, it is of note
that a truncated and activated ErbB2was used in the RCAS vector. The
wild type ErbB2 was used in the MMTV-ErbB2 line used for previous
antiestrogenic experiments, but ErbB2 is, nevertheless, somatically
mutated to an activated version in most of the tumors arising in this
transgenic line [49].
Finally, in the transgenic tumor models, the transgenic promoter
MMTV LTR is regulated by several hormones including progesterone
[17,18]; thus, hormonemanipulations such as ovariectomy or through
the use of tamoxifen in these models may incidentally reduce the level
of transgenic oncogene, jeopardizing the interpretation of the results
from the use of these conventional models. Although it did not seem
to affect progesterone signaling in cultured MCF7 cancer cells [53],
tamoxifen has been shown to significantly reduce PR levels in normal
mammary cells in vivo [54]. We are able to avoid this complication in
our study: The MMTV-tva transgenic product is only required for the
initial viral infection, and the expression of ErbB2 or PyMT in the in-
fected cells is solely controlled by the proviral RCAS LTR, which we
confirmed to be unaffected by ovariectomy (Figure W2).
In conclusion, this in vivo study in a somatic mouse model suggests
that activation of ErbB2 or other growth factor signaling pathways
causes normal ER− cells as well as some normal ER+ cells to undergo
estrogen-independent proliferation and evolution to breast carci-
nomas. These data suggest that prophylactic estrogen deprivation ther-
apy cannot prevent breast cancer initiation from mammary epithelial
cells that have gained certain genetic alterations, especially those en-
coding components of growth factor signaling pathways, and that ther-
apeutic agents that target growth factor signaling pathways may be an
important complement to antiestrogens in achieving more effective
prevention against both ER+ and ER− breast cancers in at-risk women.
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Figure W1. Tamoxifen cannot prevent tumorigenesis induced by
RCAS-PyMT or RCAS-ErbB2. (A) Six-week-old mice were infected
with RCAS-PyMT. Oneweek later,micewere randomized and divided
into either vehicle (n=23) or tamoxifen (n=24) groups.No difference
in tumor latency was detected (P = .2). (B) 10- to 12-week-old mice
were infected with RCAS-ErbB2. One week later, mice were random-
ized and divided into either vehicle (n = 13) or tamoxifen (n = 15)
groups. No difference in tumor latency was detected (P = .3).
Figure W2. The level of ErbB2 expression under control of the
RCAS LTR is not affected by ovariectomy. (A) Adult mice were in-
fected with RCAS-ErbB2. One week later, mice were randomized,
and either ovariectomy (n = 9) or sham surgery (n = 9) was per-
formed. Two weeks later, mice were killed. ErbB2 was detected by
IHC against HA. The levels of ErbB2 expression are equivalent in
intact and ovariectomized mice. Scale bar, 20 μm. (B and C) Tumor
lysates from intact (n = 7) and ovariectomized mice (n = 6) were
analyzed for ErbB2 byWestern blot analysis for the HA tag in ErbB2
(B). Theabundanceof ErbB2 relative toGAPDH is shown in the scatter
plot (C). There are equivalent levels of ErbB2 in tumors of intact and
ovariectomized mice (P = .4). Bar indicates median value.
Figure W3. The effect of ovariectomy on downstream signaling by ErbB2 in RCAS-ErbB2–induced mammary tumors. (A and B) Tumor
lysates from intact (n= 7) and ovariectomized mice (n= 6) were analyzed for total Erk and phospo-Erk (p-Erk) byWestern blot analysis (A).
The abundance of activated p-Erk relative to GAPDH is shown in the scatter plot (B). pErk is equivalent in tumors of intact and ovariecto-
mized mice (P= .8). Bar indicates mean value. (C and D) Tumor lysates from intact (n= 7) and ovariectomized mice (n= 6) were analyzed
for total AKT and phospo-AKT (p-AKT) byWestern blot analysis (C). The abundance of p-AKT relative to GAPDH is shown in scatter plot (D).
p-AKT is slightly reduced in tumors arising in ovariectomized mice (P = .05). Bar indicates mean value.
Figure W4. ER− and ER+ tumors arising from somatic activation of
ErbB2 display similar proliferation rates. (A and B) ER− (n = 5) and
ER+ (n = 4) tumors were immunostained for Ki67 (A). The percent-
age of Ki67+ cells is shown in the scatter plot (B). There is no differ-
ence in the proliferation rate (P = .5). Bar indicates median value.
